Product stability
Is the interaction reliable enough for controlled evaluation?
VALIDATION & TRUST
The current prototype, the questions for controlled evaluation and the human responsibilities that guide development.
HUMAN AUTHORITY
Qualified professionals retain clinical responsibility. Somerilo supports organization and understanding.
CURRENT
Natural text conversation, documents, follow-up, additional information and evolving case context.
The product is not clinically validated or production-ready. It does not act as an autonomous genetic specialist or diagnostic engine.
VALIDATING
Evaluation questions, rather than proven results. Controlled pilots should define scope, responsibilities and evidence requirements before they begin.
Is the interaction reliable enough for controlled evaluation?
Does the approach fit meaningful genetics workflows?
Is it useful and understandable to genetics and clinical users?
Do institutions see sufficient value to support a paid pilot?
Can delivery and operating economics support a repeatable model?
Are human authority, responsible boundaries, privacy and security adequately maintained?
RESPONSIBLE DEVELOPMENT
New capabilities require implementation, testing and demo-safety verification before they are presented as current.
Appropriate architecture for future clinical use is under evaluation. This marketing site does not collect patient information, genetic data, symptoms or medical documents.
No health-data residency or security certification is claimed.
FUTURE DIRECTION
Source-aware information is a direction. Automated provenance and source-linked answers are not verified current capabilities.
FUTURE DIRECTION
Regional and international progression depend on evidence and commercial learning. International readiness is not regulatory approval.
INTERACTION MODES